Approval Criteria Department of Pharmacy Services

**Generic Name:** Ethinyl estradiol and etonogestrel

**Brand Name:** NuvaRing®

**Medication Class:** Contraceptive; Estrogen and Progestin Combination

**FDA Approved Uses**
- Prevention of pregnancy

**Criteria for use**
- Clinical documentation that the patient is intolerant to oral contraceptives
  - AND
- Clinical documentation that the patient is unable to tolerate injectable medroxyprogesterone

**Not Approved For**
Any use other than contraception

**Required Medical Information**
- Clinical documentation of dates when oral contraceptives were trialed and response to therapy.
- Clinical documentation of dates when medroxyprogesterone injection were administered and response to therapy.

**Contraindications**
- Hypersensitivity to ethinyl estradiol, etonogestrel, or any component of the formulation
- Breast cancer or other estrogen- or progestin-dependent neoplasms (current or history or)
- Hepatic tumors or disease
- Pregnancy
- Undiagnosed abnormal uterine bleeding
- Cholestatic jaundice of pregnancy
- Jaundice with prior combination hormonal contraceptive use

**Dosing**
- One ring, inserted vaginally and left in place for 3 consecutive weeks, then removed for one week.
  - A new ring is inserted 7 days after the last was removed (even if bleeding is not complete) and should be inserted at approximately the same time of day the ring was removed the previous week.

**Authorization**
- Up to one year

Approved by P&T: 3/19/2013

**References**
3. Centers for Disease Control and Prevention (CDC), “Update to CDC’s U.S. Medical Eligibility Criteria for Contraceptive Use, 2010: Revised Recommendations for the Use of Contraceptive Methods During the Postpartum Period,” *MMWR*


